![ProsTIC/PCF Global Webinar 2023: 225-Actinium-PSMA-617: Data and Perspectives from a Medical Oncologist ProsTIC/PCF Global Webinar 2023: 225-Actinium-PSMA-617: Data and Perspectives from a Medical Oncologist](https://www.urotoday.com/images/com-doc-importer/128-prostic-pcf-global-webinar-2023/prostic-pcf-global-webinar-2023-225-actinium-psma-617-data-and-perspectives-from-a-medical-oncologist/image-0.jpg)
ProsTIC/PCF Global Webinar 2023: 225-Actinium-PSMA-617: Data and Perspectives from a Medical Oncologist
![225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study | European Journal of Nuclear Medicine and Molecular Imaging 225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study | European Journal of Nuclear Medicine and Molecular Imaging](https://media.springernature.com/m685/springer-static/image/art%3A10.1007%2Fs00259-018-4167-0/MediaObjects/259_2018_4167_Fig3_HTML.png)
225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study | European Journal of Nuclear Medicine and Molecular Imaging
![Frontiers | Current role of prostate-specific membrane antigen-based imaging and radioligand therapy in castration-resistant prostate cancer Frontiers | Current role of prostate-specific membrane antigen-based imaging and radioligand therapy in castration-resistant prostate cancer](https://www.frontiersin.org/files/Articles/958180/fcell-10-958180-HTML/image_m/fcell-10-958180-g001.jpg)
Frontiers | Current role of prostate-specific membrane antigen-based imaging and radioligand therapy in castration-resistant prostate cancer
![Structural formula of [ 225 Ac]Ac-PSMA-I&T, with DOTAGA as a chelator.... | Download Scientific Diagram Structural formula of [ 225 Ac]Ac-PSMA-I&T, with DOTAGA as a chelator.... | Download Scientific Diagram](https://www.researchgate.net/publication/351584466/figure/fig1/AS:1024889205047296@1621364036254/Structural-formula-of-225-AcAc-PSMA-I-T-with-DOTAGA-as-a-chelator-Structural.png)
Structural formula of [ 225 Ac]Ac-PSMA-I&T, with DOTAGA as a chelator.... | Download Scientific Diagram
![225Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer | Journal of Nuclear Medicine 225Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer | Journal of Nuclear Medicine](https://jnm.snmjournals.org/content/jnumed/57/12/1941/F3.large.jpg)
225Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer | Journal of Nuclear Medicine
![Pharmaceutics | Free Full-Text | Efficacy and Safety of [225Ac]Ac-PSMA-617 Augmented [177Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Highly Advanced mCRPC with Poor Prognosis Pharmaceutics | Free Full-Text | Efficacy and Safety of [225Ac]Ac-PSMA-617 Augmented [177Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Highly Advanced mCRPC with Poor Prognosis](https://www.mdpi.com/pharmaceutics/pharmaceutics-13-00722/article_deploy/html/images/pharmaceutics-13-00722-g002.png)
Pharmaceutics | Free Full-Text | Efficacy and Safety of [225Ac]Ac-PSMA-617 Augmented [177Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Highly Advanced mCRPC with Poor Prognosis
![Pharmaceutics | Free Full-Text | Development of [225Ac]Ac-PSMA-I&T for Targeted Alpha Therapy According to GMP Guidelines for Treatment of mCRPC Pharmaceutics | Free Full-Text | Development of [225Ac]Ac-PSMA-I&T for Targeted Alpha Therapy According to GMP Guidelines for Treatment of mCRPC](https://www.mdpi.com/pharmaceutics/pharmaceutics-13-00715/article_deploy/html/images/pharmaceutics-13-00715-g001.png)
Pharmaceutics | Free Full-Text | Development of [225Ac]Ac-PSMA-I&T for Targeted Alpha Therapy According to GMP Guidelines for Treatment of mCRPC
![⁶⁸Ga-PSMA-11 PET/CT scans of a representative patient with mCRPC after... | Download Scientific Diagram ⁶⁸Ga-PSMA-11 PET/CT scans of a representative patient with mCRPC after... | Download Scientific Diagram](https://www.researchgate.net/publication/337451979/figure/fig2/AS:941401936236555@1601459120845/Ga-PSMA-11-PET-CT-scans-of-a-representative-patient-with-mCRPC-after-1-cycle-of.png)
⁶⁸Ga-PSMA-11 PET/CT scans of a representative patient with mCRPC after... | Download Scientific Diagram
![18F]-Labeled PARP-1 PET imaging of PSMA targeted alpha particle radiotherapy response | Scientific Reports 18F]-Labeled PARP-1 PET imaging of PSMA targeted alpha particle radiotherapy response | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41598-022-17460-0/MediaObjects/41598_2022_17460_Fig1_HTML.png)
18F]-Labeled PARP-1 PET imaging of PSMA targeted alpha particle radiotherapy response | Scientific Reports
![First clinical results for PSMA TAT using Ac-225-PSMA-I&T in advanced mCRPC patients - Oncidium Foundation First clinical results for PSMA TAT using Ac-225-PSMA-I&T in advanced mCRPC patients - Oncidium Foundation](https://www.oncidiumfoundation.org/wp-content/uploads/2020/10/EjeSETLVkAAoMva-scaled.jpg)
First clinical results for PSMA TAT using Ac-225-PSMA-I&T in advanced mCRPC patients - Oncidium Foundation
![Efficacy and safety of 225Ac-PSMA-617 targeted alpha therapy in metastatic castration-resistant Prostate Cancer patients Efficacy and safety of 225Ac-PSMA-617 targeted alpha therapy in metastatic castration-resistant Prostate Cancer patients](https://www.thno.org/v10/p9364/toc.jpg)